FIV vaccine development and its importance to veterinary and human medicine: A review: FIV vaccine 2002 update and review

Veterinary Immunology and Immunopathology

Volumn 90, Issue 3-4, 2002, Pages 113-132

  Uhl, E W ^a   Heaton Jones, T G ^a   Pu, R ^a   Yamamoto, J K ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

FIV; Review; Vaccine

Indexed keywords

CHOLERA TOXIN; CORONA VIRUS VACCINE; CYTOKINE; DNA VACCINE; ENV C2 PEPTIDE; FELINE IMMUNODEFICIENCY VIRUS VACCINE; FELINE LEUKEMIA VIRUS VACCINE; FORT DODGE ADJUVANT; FREUND ADJUVANT; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; LENTIVIRUS VACCINE; MAREK DISEASE VACCINE; MULTIPLE ANTIGENIC PEPTIDE V3; PALMITOYL THIOESTER V3; PRIMUCELL; PROTEIN CRFK; PROTEIN RECSU; PROTEIN SIV ENV; PROTEIN SU; PROTEIN TM; PROTEIN V3; PROTEIN VACCINE; QUILLAJA SAPONIN ADJUVANT; RECOMBINANT VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; WATER OIL CREAM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; BIRD DISEASE; CANCER CONTROL; CAT DISEASE; CELL TYPE; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; CORONAVIRUS; DIAGNOSTIC TEST; DRUG APPROVAL; DRUG CROSS REACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FELINE IMMUNODEFICIENCY VIRUS; FIBROSARCOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTE COUNT; NEOPLASM; NEUROPATHY; NONHUMAN; PATHOGENESIS; RETROVIRUS INFECTION; REVIEW; TREATMENT OUTCOME; VACCINE PRODUCTION; VETERINARY MEDICINE; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; IMMUNOLOGY; PATHOGENICITY; VIROLOGY;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRUS;

AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; LENTIVIRUS INFECTIONS; VETERINARY MEDICINE; VIRAL VACCINES;

EID: 0036891575     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2427(02)00227-1     Document Type: Review

References (117)

1. Ackley C.D., Yamamoto J.K., Levy N.B., Pedersen N.C., Cooper M.D. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J. Virol. 64:1990;5652-5655.
2. Bachmann M.H., Mathiason-Dubard C., Learn G.H., Rodrigo A.G., Sodora D.L., Mazzetti P., Hoover E.A., Mullins J.I. Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and distinct evolutionary rates among envelope sequence clades. J. Virol. 71:1997;4241-4253.
3. Barlough J.E., Ackley C.D., George J.W., Levy N., Acevedo R., Moore P.F., Rideout B.A., Cooper M.D., Pedersen N.C. Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infection. J. Acquir. Immune Defic. Syndr. 4:1991;219-227.
4. Beaumont T., Broersen S., van Nuenen A., Juisman J.G., de Roda Husman A.-M., Heeney J.L., Schuitemaker J. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J. Virol. 74:2000;7699-7707.
5. Bendinelli M., Pistello M., Lombardi S., Poli A., Garzelli C., Matteucci D., Ceccherini-Nelli L., Malvaldi G., Tozzini F. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin. Microbiol. Rev. 8:1995;87-112.
6. Blackard J.T., Cohen D.E., Mayer K.H. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin. Infect. Dis. 34:2002;1108-1114.
7. Bootman J.S., Kitchin P.A. Reference preparation in the standardisation of HIV-1 PCR - an international collaborative study. J. Virol. Meth. 49:1994;1-8.
8. Boretti F.S., Leutenegger C.M., Mislin C., Hofmann-Lehmann R., Konig S., Schroff M., Junghans C., Fehr D., Huettner S.W., Habel A., Flynn J.N., Aubert A., Pedersen N.C., Wittig B., Lutz H. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV Env gene and feline IL-12 expression. AIDS. 14:2000;1749-1757.
9. Burkhard M.J., Mathiason C.K., O'Halloran K., Hoover E.A. Kinetics of early FIV infection in cats exposed via the vaginal versus intravenous route. AIDS Res. Hum. Retrov. 18:2002;217-226.
10. Calabrese L.H., Kelley D.M., Myers A., O'Connell M., Easley K. Rheumatic symptoms and human immunodeficiency virus infection. The influence of clinical and laboratory variables in a longitudinal cohort study. Arthritis Rheum. 34:1991;257-263.
11. Callanan J.J., Thompson H., Toth S.R., O'Neil B., Lawrence C.E., Willett B., Jarrett O. Clinical and pathological findings in feline immunodeficiency virus experimental infection. Vet. Immunol. Immunopathol. 35:1992;3-13.
12. Callanan J.J., Jones B.A., Irvine J., Willett B.J., McCandlish I.A.P., Jarrett O. Histologic classification and immunophenotype of lymphosarcomas in cats with naturally and experimentally acquired feline immunodeficiency virus infections. Vet. Pathol. 33:1996;264-272.
13. Calnek B.W. Marek's disease vaccines. Dev. Biol. Stand. 52:1982;401-405.
14. Calnek, B.W., Witter, R.L., 1997. Marek's disease. In: Calnek, B.W., Barnes, H.J., Beard, C.W., McDougald, L.R., Saif, Y.M. (Eds.), Diseases of Poultry, 10th ed. Iowa State University Press, Ames, Iowa, pp. 369-413.
15. Chiarantini L., Matteucci D., Pistello M., Mancini U., Mazzetti P., Massi C., Giannecchini S., Lonetti I., Magnani M., Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens. Clin. Diag. Lab. Immunol. 5:1998;235-241.
16. Choi I.S., Hokanson R., Collisson E.W. Anti-feline immunodeficiency virus (FIV) soluble factor(s) produced from antigen-stimulated feline CD8(+) T lymphocytes suppresses FIV replication. J. Virol. 74:2000;676-683.
17. Client Information Series, 1990. Feline immunodeficiency virus. Feline Pract. 18 21-24.
18. Cuisinier A.M., Meyer A., Chatrenet B., Verdier A.S., Aubert A. Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection. Vaccine. 17:1999;415-425.
19. D'Souza M.P., Livnat D., Bradac J.A., Bridges S.H. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J. Infect. Dis. 175:1997;1056-1062.
20. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 258:1992;1938-1941.
21. Desrosiers R.C., Bolognesi D.P. Controversies in science: a live virus AIDS vaccine? J. NIH Res. 6:1994;54-62.
22. Diehl L.J., Mathiason-Dubard C.K., O'Neil L.L., Obert L.A., Hoover E.A. Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage. J. Virol. 69:1995;6149-6157.
23. Dunham S.P., Flynn J.N., Rigby M.A., Macdonald J., Bruce J., Cannon C., Golder M.C., Hanlon L., Harbour D.A., Mackay N.A., Spibey N., Jarrett O., Neil J.C. Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18. Vaccine. 20:2002;1483-1496.
24. Egberink H., Keldermans L., Schuurman N., Stam J., Hesselin W., van Vliet A., Verschoor E., Horzinek M., de Ronde A. Monoclonal antibodies to immunodominant and neutralizing domains of the envelope surface protein of feline immunodeficiency virus. J. Gen. Virol. 75:1994;889-893.
25. Elyar J., Tellier M.C., Soos J.M., Yamamoto J.K. Perspectives on FIV vaccine development. Vaccine. 15:1997;1437-1444.
26. English R.V., Johnson C.M., Gebhard D.H., Tompkins M.B. In vivo lymphocyte tropism of feline immunodeficiency virus. J. Virol. 67:1993;5175-5186.
27. Fauci A., Schnittman S., Poli G., Koenig S., Pantaleo G. Immunopathogenic mechanisms of human immunodeficiency virus (HIV) infection. Ann. Inter. Med. 114:1991;678-693.
28. Fehr D., Holznagel E., Bolla S., Hauser B., Herrewegh A.A.P.M., Horzinek M.C., Lutz H. Placebo-controlled evaluation of a modified live virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions. Vaccine. 15:1997;1101-1109.
29. Feline Medicine Advisory Panel, 2000. Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Vaccines, pp. 1-27 ( http://www.aafponline.org/about/guidelines.htm ).
30. Feline Medicine Advisory Panel, 2001. Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Retrovirus Testing and Management ( http://www.aafponline.org/about/guidlines.htm ).
31. Finerty S., Stokes C.R., Gruffydd-Jones T.J., Hillman T.J., Reeves N.A., Whiting C.V., Schaaper W.M., Dalsgaard K., Harbour D.A. Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge. Vaccine. 18:2000;3254-3265.
32. Finerty S., Stokes C.R., Gruffydd-Jones T.J., Hillman T.J., Barr F.J., Harbour D.A. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine. 20:2002;49-58.
33. Flynn J.N., Beatty J.A., Cannon C.A., Stephens E.B., Hosie M.J., Neil J.C., Jarrett O. Involvement of Gag- and Env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus. AIDS Res. Hum. Retrov. 11:1995;1107-1113.
34. Flynn J.N., Cannon C.A., Sloan D., Neil J.C., Jarrett O. Suppression of feline immunodeficiency virus replication in vitro by a soluble factor secreted by CD8+ T lymphocytes. Immunology. 96:1999;220-229.
35. Fort Dodge Animal Health, 2002a. Fort Dodge Animal Health Received USDA Approval for a Feline Immunodeficiency Virus Vaccine for Cats. Press Release March 25, 2002 ( http://www.wyeth.com/news/pressed_and_released/pr03_25_2002.html ).
36. Fort Dodge Animal Health, 2002b. Fel-O-Vax FIV product insert released on July 14, 2002.
37. Garrett, L., 2001. Skeptical about AIDS vaccine/testing method questioned. Newsday September 5, 2001 ( http://www.aegis.com/news/newsday/2001/ND010901.html ).
38. Gebhard D.H., Dow J.L., Childers T.A., Alvelo J.I., Tompkins M.B., Tompkins W.A.F. Progressive expansion of an L-selectin-negative CD8 cell with anti-feline immunodeficiency virus (FIV) suppressor function in the circulation of FIV-infected cats. J. Infect. Dis. 180:1999;1503-1513.
39. Gerber J.D., Ingersoll J.D., Gast A.M., Christianson K.K., Selzer N.L., Landon R.M., Pfeiffer N.E., Sharpee R.L., Bechenhauer W.H. Protection against feline infectious peritonitis by intranasal inoculation of a temperature-sensitive FIPV vaccine. Vaccine. 8:1990;536-542.
40. Giannecchini S., del Mauro D., Matteucci D., Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies. J. Virol. 75:2001;4424-4429.
41. Girard M., Habel A., Chanel C. New prospects for the development of a vaccine against human immunodeficiency virus type 1: an overview. CR Acad. Sci. III. 322:1999;959-966.
42. Gobar G.M., Kass P.H. World wide web-based survey of vaccination practices, postvaccinal reactions and vaccine site-associated sarcomas in cats. JAVMA. 220:2002;1477-1482.
43. Hartmann K. Feline immunodeficiency virus infection: an overview. Vet. J. 155:1998;123-137.
44. Hartmann K., Werner R.M., Egberink H., Jarrett O. Comparison of six in-house tests for the rapid diagnosis of feline immunodeficiency and feline leukemia virus infection. Vet. Rec. 149:2001;317-320.
45. Hendrick M.J., Brooks J.J. Postvaccinal sarcomas in the cat: histology and immunochemistry. Vet. Pathol. 31:1994;126-129.
46. Hesselink W., Sondermeijer P., Pouwels H., Verblakt E., Dhore C. Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge. Vet. Microbiol. 69:1999;109-110.
47. Hoffmann-Fezer G., Thum J., Ackley C., Herbold M., Mysliwietz J., Thefeld S., Hartmann K., Kraft W. Decline in CD4+ cell numbers in cats with naturally acquired feline immunodeficiency virus infection. J. Virol. 66:1992;1484-1488.
48. Hofmann-Lehmann R., Holznagel E., Ossent P., Lutz H. Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets. Clin. Diag. Lab. Immunol. 4:1997;33-42.
49. Hohdatsu T., Okada S., Motokawa K., Yamamoto J.K., Koyama H. Effect of dual-subtype vaccine against feline immunodeficiency virus infection. Vet. Microbiol. 58:1997;155-165.
50. Hoover E.A., Mullins J.I., Chu H.-J., Wasmoen T.L. Efficacy of an inactivated feline leukemia virus vaccine. AIDS Res. Hum. Retrov. 12:1996;379-383.
51. Hopper C.D., Sparkes A.H., Gruffydd-Jones T.J., Crispin S.M., Muir P., Harbour D.A., Stokes C.R. Clinical and laboratory findings in cats infected with feline immunodeficiency virus. Vet. Rec. 125:1989;341-346.
52. Hosie M.J., Osborne R., Reid G., Neil J.C., Jarrett O. Enhancement after feline immunodeficiency virus vaccination. Vet. Immunol. Immunopathol. 35:1992;191-197.
53. Hosie M.J., Osborne R., Thompson F.J., Yamamoto J.K., Neil J.C., Jarrett O. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J. Virol. 69:1995;1253-1255.
54. Hosie M.J., Flynn J.N., Cannon C., Dunsford T., Mackay N.A., Argyle D., Willet B.J., Miyazawa T., Onions D.E., Jarrett O., Neil J.C. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J. Virol. 72:1998;7310-7319.
55. Hosie M.J., Dunsford T., Klein D., Willett B.J., Cannon C., Osborne R., MacDonald J., Spibey N., Mackay N., Jarrett O., Neil J.C. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J. Virol. 74:2000;9403-9411.
56. Huisman W., Karlas J.A., Siebelink K.H.J., Huisman R.C., de Ronde A., Francis M.J., Rimmelzwaan G.F., Osterhaus A.D.M.E. Feline immunodeficiency virus subunit vaccines that induce neutralising antibodies but no protection against challenge infection. Vaccine. 16:1998;181-187.
57. Inoshima Y., Ikeda Y., Kohmoto M., Pecoraro M.R., Shimojima M., Shimojima Y., Inada G., Kawaguchi Y., Tomonaga K., Miyazawa T., Mikami T. Persistence of high virus neutralizing antibody titers in cats experimentally infected with feline immunodeficiency virus. J. Vet. Med. Sci. 58:1996;925-927.
58. Inoshima Y., Mihyzawa T., Kohmoto M., Ikeda Y., Sato E., Hohdatsu T., Mathiason-Dubard C., Hoover E.A., Mikami T. Cross virus neutralizing antibodies against feline immunodeficiency virus genotypes A, B, D and E. Archiv. Virol. 143:1998;157-162.
59. Ishida T., Washizu T., Toriyabe K., Motoyoshi S., Tomoda I., Pedersen N. Feline immunodeficiency virus infection in cats of Japan. J. Am. Vet. Med. Assoc. 194:1989;221-225.
60. Johnson R.P. Macaque models for AIDS vaccine development. Curr. Opin. Immunol. 8:1996;554-560.
61. Johnston M.I., Flores J. Progress in HIV vaccine development. Curr. Opin. Pharmacol. 1:2001;504-510.
62. Karlas J.A., Siebelink K.H.J., van Peer M.A., Huisman W., Rimmelzwaan G.F., Osterhaus A.D.M.E. Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells. Vet. Immunol. Immunopathol. 65:1998;353-356.
63. Karlas J.A., Siebelink K.H.J., van Peer M.A., Huisman W., Cuisinier A.M., Rimmelzwaan G.F., Osterhaus A.D.M.E. Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J. Gen. Virol. 80:1999;761-765.
64. Klein D., Janda P., Steinborn R., Muller M., Salmons B., Gunzburg W.H. Proviral load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: influence of mismatches on quantification. Electrophoresis. 20:1999;291-299.
65. Klein D., Leutenegger C.M., Bahula C., Gold P., Hofmann-Lehmann R., Salmons B., Lutz H., Gunzburg W.H. Influence of preassay and sequence variations on viral load determination by a multiplex real-time reverse transcriptase-polymerase chain reaction for feline immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 26:2001;8-20.
66. Kohmoto M., Miyazawa T., Sato E., Uetsuka K., Nishimura Y., Ikeda Y., Inada G., Doi K., Mikami T. Cats are protected against feline immunodeficiency virus following vaccination with a homologous AP-1 binding site-deleted mutant. Archiv. Virol. 143:1998;1839-1845.
67. Lawler, D.F., Evans, R.H., 1997. Strategies for controlling viral infections in feline populations. In: August, J.R. (Ed.), Consultations in Feline Internal Medicine, vol. 3. Saunders, Philadelphia, PA, Chapter 76, pp. 603-610.
68. Legendre A.M., Hawks D.M., Sebring R., Rohrbach B., Chavez L., Chu H.-J., Acree W.M. Comparison of the efficacy of three commercial feline leukemia virus vaccines in a natural challenge exposure. J. Am. Vet. Med. Assoc. 199:1991;1456-1462.
69. Leutenegger C.M., Hofmann-Lehmann R., Holznagel E., Cuisinier A.M., Wolfensberger C., Duquesne V., Cronier J., Allenspach K., Aubert A., Ossent P., Lutz H. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins. AIDS Res. Hum. Retrov. 14:1998;275-283.
70. Leutenegger C.M., Boretti F.S., Mislin C.N., Flynn J.N., Schroff M., Habel A., Junghans C., Koenig-Merediz S.A., Sigrist B., Aubert A., Pedersen N.C., Wittig B., Lutz H. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif. J. Virol. 74:2000;10447-10457.
71. Li J., Brown W.C., Song W., Carpino M.R., Wolf A.M., Grant C.K., Elder J.H., Collisson E.W. Retroviral vector-transduced cells expressing the core polyprotein induce feline immunodeficiency virus-specific cytotoxic T-lymphocytes from infected cats. Virus Res. 38:1995;93-109.
72. Liang Y., Hudson L.C., Levy J.K., Ritchey J.W., Tompkins W.A., Tompkins M.B. T cells overexpressing interferon-gamma and interleukin-10 are found in both the thymus and secondary lymphoid tissues of feline immunodeficiency virus-infected cats. J. Infect. Dis. 181:2000;564-575.
73. Lockridge, K.M., Himathongkham, S., Sawai, E.T., Chienand, M., Sparger, E.E., 1999. The feline immunodeficiency virus vif gene is required for productive infection of feline peripheral blood mononuclear cells and monocyte-derived macrophages. Virology 261, 25-30.
74. Lockridge K.M., Chien M., Dean G.A., Cole K.S., Montelaro R.C., Luciw P.A., Sparger E.E. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology. 273:2000;67-79.
75. Lombardi S., Garzelli C., la Rosa C., Zaccaro L., Spector S., Malvaldi G., Tozzini F., Esposito F., Bendinelli M. Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. J. Virol. 67:1993;4742-4749.
76. Macy, D.W., 1994. Vaccination against feline retroviruses. In: August, J.R. (Ed.), Consultations in Feline Internal Medicine, vol. 2. Saunders, Philadelphia, PA, Chapter 5, pp. 33-39.
77. Matteucci D., Pistello M., Mazzetti P., Giannecchini S., del Mauro D., Zaccaro L., Bandecchi P., Tozzini F., Bendinelli M. Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J. Virol. 70:1996;617-622.
78. Matteucci D., Pistello M., Mazzetti P., Giannecchini S., del Mauro D., Lonetti I., Zaccaro L., Pollera C., Specter S., Bendinelli M. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. J. Virol. 71:1997;8368-8376.
79. Matteucci D., Pistello M., Mazzetti P., Giannecchini S., Isola P., Merico A., Zaccaro L., Rizzuti A., Bendinelli M. AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. Vaccine. 18:1999;119-130.
80. Matteucci D., Poli A., Mazzetti P., Sozzi S., Bonci F., Isola P., Zaccaro L., Giannecchini S., Calandrella M., Pistello M., Specter S., Bendinelli M. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J. Virol. 74:2000;10911-10919.
81. McArdle F., Tennant B., Kelly D.F., Gaskell C.J., Gaskell R.M. Independent evaluation of a modified live FIPV vaccine under experimental conditions (University of Liverpool experience). Feline Pract. 23:1995;67-71.
82. Mooij P., Heeney J.L. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine. 20:2002;304-321.
83. Nabel G.J. Challenges and opportunities for development of an AIDS vaccine. Nature. 410:2001;1002-1007.
84. Nicodemus, J., Sbai, H., De Groot, A.S., 2001. Urgency and Optimism at the AIDS Vaccine 2001 Conference, AIDScience vol. 1, October 4-11, 2001 ( http://aidscience.org/Articles/aidscience009.pdf ).
85. Norsworthy, G.D. (Ed.), 1993a. Feline infectious peritonitis. In: Feline Practice. Lippincott, Philadelphia, PA, pp. 352-359.
86. Norsworthy, G.D. (Ed.), 1993b. Feline leukemia virus diseases. In: Feline Practice. Lippincott, Philadelphia, PA, pp. 360-368.
87. Obert L.A., Hoover E.A. Relationship of lymphoid lesions to disease course in mucosal feline immunodeficiency virus type C infection. Vet. Pathol. 37:2000;386-401.
88. Pedersen N.C., Ho E.W., Brown M.L., Yamamoto J.K. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science. 235:1987;790-793.
89. Gammar) in young adult specific pathogen free cats. Vet. Immunol. Immunopathol. 79:2001;53-67.
90. Pu R., Coleman J., Omori M., Mison M., Huang C., Arai M., Tanabe T., Yamamoto J.K. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS. 15:2001;1-13.
91. Rideout B.A., Moore P.F., Pedersen N.C. Persistent up regulation of MHC class II antigen expression on T-lymphocytes from cats experimentally infected with feline immunodeficiency virus. Vet. Immunol. Immunopathol. 35:1992;71-81.
92. Schnell M.J. Viral vectors as potential HIV-1 vaccines. FEMS Microbiol. Lett. 200:2001;123-129.
93. Scott, F.W., 1999. Evaluation of risks and benefits associated with vaccination against corona virus infections in cats. In: Schultz, R.D. (Ed.), Veterinary Vaccines and Diagnostics. Academic Press, San Diego, pp. 347-358.
94. Scott F.W., Corapi W.V., Olsen C.W. Independent evaluation of a modified live FIPV vaccine under experimental conditions (Cornell experience). Feline Pract. 23:1995;74-76.
95. Siebelink K.H.J., Chu I.-H., Rimmelzwaan G.F., Weijer K., Herwijnen R.V., Knell P., Egberink H.F., Bosch M.L., Osterhaus A.D.M.E. Feline immunodeficiency virus (FIV) infection in the cat as a model for HIV infection in man: FIV-induced impairment of immune function. AIDS Res. Hum. Retrov. 6:1990;1373-1378.
96. Song W., Collison E., Billingsley P., Brown W. Induction of feline immunodeficiency virus specific cytotoxic T-cell responses from experimentally infected cats. J. Virol. 66:1992;5409-5417.
97. Sparkes A.H. Feline leukaemia virus: a review of immunity and vaccination. J. Small Anim. Pract. 38:1997;187-194.
98. Stokes C.R., Finerty S., Gruffydd-Jones T.J., Sturgess C.P., Harbour D.A. Mucosal infection and vaccination against feline immunodeficiency virus. J. Biotechnol. 73:1999;213-221.
99. Stott E.J. Anti-cell antibody in macaques. Nature. 353:1991;393.
100. Taniguchi A., Ishida T., Washizu T., Tomoda I. Humoral immune response to T-cell dependent and independent antigens in cats infected with feline immunodeficiency virus. J. Vet. Med. Sci. 53:1991;333-339.
101. Tellier M.C., Soos J.M., Pu R., Pollock D., Yamamoto J.K. Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunization with FIV vaccines. Vet. Microbiol. 57:1997;1-11.
102. Tellier M.C., Pu R., Pollock D., Vitsky A., Tartaglia J., Paoletti E., Yamamoto J.K. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats. AIDS. 12:1998;11-18.
103. Terry A., Callanan J.J., Fulton R., Jarrett O., Neil J.C. Molecular analysis of tumors from feline immunodeficiency virus (FIV)-infected cats: an indirect role for FIV? Int. J. Cancer. 61:1995;227-232.
104. Torten M., Franchini M., Barlough J.E., George J.W., Mozes E., Lutz J., Pedersen N.C. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J. Virol. 65:1991;2225-2230.
105. USDA, 2001. Center for Veterinary Biologics. In: UDSA Veterinary Biological Products: Licensee and Permittees, June 2001. USDA, IA ( http://www.aphis.usda.gov/vs/cvb/lpd ).
106. USDA, 2002. USDA issues license for feline immunodeficiency virus vaccine for cats. Press release March 2002 (http://www.aphis.usda.gov/lpa/press/2002/03/catvac.txt ).
107. Vahlenkamp T.W., de Ronde A., Horzinek M.C., Egberink H.F. Quantification of feline immunodeficiency virus (FIV) RNA in the plasma of infected cats. Berlin Munch. Tierarztl. Wochenschr. 109:1996;265-269.
108. van Kampen K.R. Recombinant vaccine technology in veterinary medicine. Vet. Clin. North Am. Small Anim. Pract. 31:2001;535-538.
109. Venugopal K. Marek's disease: an update on oncogenic mechanisms and control. Res. Vet. Sci. 69:2000;17-23.
110. Wyand M.S., Manson K.H., Garcia-Moll M., Montefiori D.C., Desrosiers R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:1996;3724-3733.
111. Yamaguchi J., Vallari A.S., Swanson P., Bodelle P., Kaptue L., Ngansop C., Zekeng L., Gurtler L.G., Devare S.G., Brennan C.A. Evaluation of HIV type 1 group O isolates: identification of five phylogenetic clusters. AIDS Res. Hum. Retrov. 18:2002;269-282.
112. Yamamoto, J.K., 1999. Feline immunodeficiency virus (Retroviridae). In: Granoff, A., Webster, R.G. (Eds.), Encyclopedia of Virology, 2nd ed. Academic Press, San Diego, pp. 535-541.
113. Yamamoto J.K., Hansen H., Ho E.W., Morishita T.Y., Okuda T., Sawa T.R., Nakamura R.M., Pedersen N.C. Epidemiologic and clinical aspects of feline immunodeficiency virus (FIV) infection in cats from the continental United States and Canada and possible mode of transmission. J. Am. Vet. Med. Assoc. 194:1989;213-220.
114. Yamamoto J.K., Hohdatsu T., Olmsted R.A., Pu R., Louie H., Zochlinski H., Acevedo V., Johnson H.M., Soulds G.A., Gardner M.B. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J. Virol. 67:1993;601-605.
115. Yamamoto, J.K., Mison, M., Elyar, J., Tellier, M., Pu, R., 1996. Efficacy evaluation of conventional dual-subtype FIV vaccine. In: Proceedings of the IX International Conference on AIDS, Vancouver, Canada, July 6-10, 1996 (oral presentation by M. Tellier). M. Tellier received Young Investigator Award for this abstract in the IX International Conference on AIDS.
116. Yamanouchi K., Barrett T., Kai C. New approaches to the development of virus vaccines for veterinary use. Rev. Sci. Tech. 17:1998;641-653.
117. Zou W., Lackner A.A., Simon M., Durand-Gasselin I., Galanaud P., Desrosiers R.C., Emilie D. Early cytokine and chemokine gene expression in lymph nodes of macaques infected with simian immunodeficiency virus is predictive of disease outcome and vaccine efficacy. J. Virol. 71:1997;1227-1236.